In this article published in Drug Development & Delivery, Pascale Diesel and Lev Gerlovin discuss how as industry works to advance cell and gene therapy development, the debate over new approaches to structuring and financial clinical research continues.
Click here to read the article.
Potential MFN impact
Reference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...